Keros Therapeutics reports Q3 EPS ($1.33), consensus ($1.35)

Reports Q3 revenue $8,000 vs. $0 last year. “Over the last quarter, we made strong progress across our pipeline and executed upon our corporate goals. We continued to advance our two open-label Phase 2 clinical trials evaluating KER-050, one in patients with myelodysplastic syndrome and one in patients with myelofibrosis, and we look forward to sharing additional data from both trials at the 65th American Society of Hematology Annual Meeting and Exposition later this quarter,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “We also continued to progress our ongoing TROPOS Phase 2 clinical trial evaluating KER-012 in patients with pulmonary arterial hypertension and activities related to global clinical trial site activation ramped up and continue to be a primary focus of our team.”